Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

被引:57
作者
Milionis, HJ
Papakostas, J
Kakafika, A
Chasiotis, G
Seferiadis, K
Elisaf, MS [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
[2] Univ Hosp Ioannina, Biochem Lab, Ioannina, Greece
关键词
atorvastatin; fenofibrate; folic acid; homocysteine; lipids; simvastatin; uric acid; vitamin B12;
D O I
10.1177/0091270003255920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyperhomocysteinemia is regarded as an independent risk factor for cardiovascular disease. Lipid-lowering agents, Such as fibrates, can modify homocysteine levels. However, less is known about the effect of statin therapy on homocysteine. The authors compared the effects of atorvastatin (40 mg/day), simvastatin (40 mg/day), and micronized fenofibrate (200 mg/day) on the serum concentrations of total homocysteine, vitamin B12, and folic acid in patients with primary hyperlipidemia. A total of 128 patients with primary hyperlipidemia (total cholesterol > 240 mg/dL and triglycerides < 350 mg/dL) were assigned to atorvostatin, simvastatin, or fenofibrate. Serum lipid and metabolic parameters were measured at baseline and at 6 and 12 weeks of treatment. Homocysteine correlated positively with serum creatinine and uric acid levels and inversely with serum folic acid levels. All treatment modalities reduced total, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations. High-density lipoprotein (HDL) cholesterol levels significantly in-creased only in the fenofibrote-treated patients (47.9 +/- 12.5 vs. 50.7 +/- 12.6 vs. 51.2 +/- 12.8 mg/dL, p < 0.01). Atorvastotin and fenofibrate treatment resulted in a significant reduction of serum uric acid levels (5.3 +/- 1.6 vs. 4.9 +/- 1.4 vs. 4.8 +/- 1.4 mg/dL, p < 0,0001 for atorvastatin; 5.6 +/- 1.6 vs. 4.3 +/- 1.4 vs. 4.4 +/- 1.4 mg/dL, p < 0.0001 for fenofibrate). Homocysteine levels were significantly increased only by fenofibrate (10.3 +/- 3.3 vs. 14.1 +/- 3.8 vs. 14.2 +/- 3.6 muU/L, p < 0.001) but did not change from baseline following statin treatment. Neither statins nor fenofibrate had any effect on serum vitamin B12 and folic acid levels. In contrast to fenofibrate, therapeutic dosages of atorvastatin and simvastatin have a neutral effect on serum homocysteine levels, which is in favor of their "cordioprotective" properties.
引用
收藏
页码:825 / 830
页数:6
相关论文
共 41 条
[1]  
BENGTSSON C, 1988, ACTA MED SCAND, V224, P549
[2]   Fenofibrate raises plasma homocysteine levels in the fasted and fed states [J].
Bissonnette, R ;
Treacy, E ;
Rozen, R ;
Boucher, B ;
Cohn, JS ;
Genest, J .
ATHEROSCLEROSIS, 2001, 155 (02) :455-462
[3]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[4]   HYPERURICEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE - THE FRAMINGHAM-STUDY [J].
BRAND, FN ;
MCGEE, DL ;
KANNEL, WB ;
STOKES, J ;
CASTELLI, WP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (01) :11-18
[5]   Implication of fibrate therapy for homocysteine [J].
Chan, N ;
Chan, JCN .
LANCET, 1999, 354 (9185) :1208-1209
[6]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155
[7]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[9]   Lipid-lowering drugs and homocysteine [J].
de Lorgeril, M ;
Salen, P ;
Paillard, F ;
Lacan, P ;
Richard, G .
LANCET, 1999, 353 (9148) :209-210
[10]   Drugs affecting homocysteine metabolism - Impact on cardiovascular risk [J].
Desouza, C ;
Keebler, M ;
McNamara, DB ;
Fonseca, V .
DRUGS, 2002, 62 (04) :605-616